Capricorn Team

Martin Götting, CEO

Martin Götting, CEO

Martin Götting brings a wealth of experience in the vaccine industry with over 20 years at Behringwerke AG and Chiron Vaccines International serving as, among others, Global Head of Production- and Sales Logistics and Director Commercial Operations. In 2005 he joined Intercell AG (today Valneva), a company focused on the development of modern prophylactic and therapeutic vaccines against infectious diseases, as Vice-President Marketing, Sales & Supply. He holds degrees in wholesale and foreign trade, pharmaceutical sales and a qualification as Legal Trade General Manager Austria.

In 2009 he founded Capricorn Consilium GmbH, Vienna, a company dedicated to consult and provide interim management predominantly to small and medium sized vaccine companies. In this capacity he contributed to numerous licensing, partnering, funding, M&A and business development activities in the vaccine industry. During this period, he has served as interim manager, predominantly for vaccine companies, being in charge of General Management including board positions, Business Development, Finance, Funding, Strategy, Human Resources, Corporate Communications, Legal, and Supply Chain Management.

Prof. Andrej Egorov, Ph.D., CSO

Prof. Andrej Egorov, Ph.D., CSO

Prof. Andrej Egorov received his MD and PhD in St. Petersburg, Russia. The initial topic of his carrier was the research and development of the live cold-adapted attenuated influenza vaccines. From 1996 he has been working as a Professor at the Institute of Applied Microbiology in Vienna, Austria. In 1998 he published his key results describing influenza NS1 protein truncated mutants defective in interferon antagonizing function. Following research (publication1, publication2, publication3)  was addressed to the development of a new generation of live influenza vaccine and vectors with manipulated NS1 genes. From 2006 until 2011 Dr. Egorov was the VP Research at Avir Green Hills Biotechnology AG, Austria. In 2016 Dr. Egorov became the founder and CSO of  Vacthera BioTech GmbH which develops attenuated influenza vaccine vectors. Since end 2018, he also serves as CSO at Capricorn.

Artem Krokhin, Ph.D.

Artem Krokhin, Ph.D., Senior Scientist

Dr. Artem Krokhin received his PhD in Chemistry from the University of Vienna, Austria. During his PhD study he was working on the development of a new chemotherapeutic anticancer agents. In 2008 he joined Fresenius Kabi Austria GmbH which is a global healthcare company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. There, he was responsible for the development of a several new active pharmaceutical ingredients for the parenteral use. Over the last 8 years he has been working on the development of a new universal live attenuated vaccine against Influenza and different viral vectors based on the Influenza virus. He has experience with a full life cycle of the development of a new live viral based vaccines − from the creation of a new recombinant viruses (plasmid transfection) to their purification (sucrose gradient centrifugation, PEG-precipitation, TFF) and formulation (stability, lyophilization) with following analysis (titration, PCR, neutralization, ELISA, WB, FACS). Dr. Krokhin joined Capricorn January 2019.